Skip to main content
Journal cover image

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.

Publication ,  Journal Article
Nguyen, HV; Bose, S; Finkelstein, E
Published in: BMC Nephrol
April 28, 2016

BACKGROUND: Sevelamer is an alternative to calcium carbonate for the treatment of hyperphosphatemia among non-dialysis dependent patients with chronic kidney disease (CKD). Although some studies show that it may reduce mortality and delay the onset of dialysis when compared to calcium carbonate, it is also significantly more expensive. Prior studies looking at the incremental cost-effectiveness of sevelamer versus calcium carbonate in pre-dialysis patients are based on data from a single clinical trial. The goal of our study is to use a wider range of clinical data to achieve a more contemporary and robust cost-effectiveness analysis. METHODS: We used a Markov model to estimate the lifetime costs and quality-adjusted life years (QALYs) gained for treatment with sevelamer versus calcium carbonate. The model simulated transitions among three health states (CKD not requiring dialysis, end-stage renal disease, and death). Data on transition probabilities and utilities were obtained from the published literature. Costs were calculated from a third party payer perspective and included medication, hospitalization, and dialysis. Sensitivity analyses were also run to encompass a wide range of assumptions about the dose, costs, and effectiveness of sevelamer. RESULTS: Over a lifetime, the average cost per patient treated with sevelamer is S$180,724. The estimated cost for patients treated with calcium carbonate is S$152,988. A patient treated with sevelamer gains, on average, 6.34 QALYs relative to no treatment, whereas a patient taking calcium carbonate gains 5.81 QALYs. Therefore, sevelamer produces an incremental cost-effectiveness ratio (ICER) of S$51,756 per QALY gained relative to calcium carbonate. CONCLUSION: Based on established benchmarks for cost-effectiveness, sevelamer is cost effective relative to calcium carbonate for the treatment of hyperphosphatemia among patients with chronic kidney disease initially not on dialysis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMC Nephrol

DOI

EISSN

1471-2369

Publication Date

April 28, 2016

Volume

17

Issue

1

Start / End Page

45

Location

England

Related Subject Headings

  • Young Adult
  • Urology & Nephrology
  • Treatment Outcome
  • Singapore
  • Sevelamer
  • Renal Insufficiency, Chronic
  • Renal Dialysis
  • Middle Aged
  • Markov Chains
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nguyen, H. V., Bose, S., & Finkelstein, E. (2016). Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. BMC Nephrol, 17(1), 45. https://doi.org/10.1186/s12882-016-0256-0
Nguyen, Hai V., Saideep Bose, and Eric Finkelstein. “Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.BMC Nephrol 17, no. 1 (April 28, 2016): 45. https://doi.org/10.1186/s12882-016-0256-0.
Nguyen, Hai V., et al. “Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.BMC Nephrol, vol. 17, no. 1, Apr. 2016, p. 45. Pubmed, doi:10.1186/s12882-016-0256-0.
Journal cover image

Published In

BMC Nephrol

DOI

EISSN

1471-2369

Publication Date

April 28, 2016

Volume

17

Issue

1

Start / End Page

45

Location

England

Related Subject Headings

  • Young Adult
  • Urology & Nephrology
  • Treatment Outcome
  • Singapore
  • Sevelamer
  • Renal Insufficiency, Chronic
  • Renal Dialysis
  • Middle Aged
  • Markov Chains
  • Male